Trinity Biotech Plc ADR [TRIB] stock is trading at $0.79, up 12.43%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TRIB shares have gain 13.04% over the last week, with a monthly amount drifted -12.08%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trinity Biotech Plc ADR [NASDAQ: TRIB] stock has seen the most recent analyst activity on October 23, 2015, when Craig Hallum downgraded its rating to a Hold. On July 29, 2015, ROTH Capital reiterated its Buy rating and revised its price target to $20 on the stock. Roth Capital reiterated its Buy rating and decreased its price target to $6 on July 22, 2008. Roth Capital reiterated its recommendation of a Buy and reduced its price target to $7 on March 17, 2008. Roth Capital reiterated a Buy rating for this stock on December 10, 2007, and downed its price target to $10.50. In a note dated October 26, 2007, Roth Capital reiterated a Buy rating on this stock and revised its target price from $13 to $11.50.
Trinity Biotech Plc ADR [TRIB] stock has fluctuated between $0.48 and $3.44 over the past year. Trinity Biotech Plc ADR [NASDAQ: TRIB] shares were valued at $0.79 at the most recent close of the market.
Analyzing the TRIB fundamentals
Trinity Biotech Plc ADR [NASDAQ:TRIB] reported sales of 48.54M for the trailing twelve months, which represents a drop of -5.96%. Gross Profit Margin for this corporation currently stands at 0.35% with Operating Profit Margin at -0.41%, Pretax Profit Margin comes in at -0.73%, and Net Profit Margin reading is -0.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is 0.81 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Trinity Biotech Plc ADR’s Current Ratio is 1.03. As well, the Quick Ratio is 0.47, while the Cash Ratio is 0.04. Considering the valuation of this stock, the price to sales ratio is 0.30.
